Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays

Journal of Virological Methods

Volumn 148, Issue 1-2, 2008, Pages 166-173

  Heyndrickx, Leo ^a   Vermoesen, Tine ^a   Vereecken, Katleen ^a   Kurth, Julia ^b   Coppens, Sandra ^a   Aerts, Laetitia ^a   Ohagen, Asa ^b   Van Herrewege, Yven ^a   Lewi, Paul ^d   Vanham, Guido ^a,c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b TIBOTEC BVBA   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d NONE   (Belgium)

Author keywords

Antiviral activity; Entry inhibitors; HIV 1; Pseudovirus

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTIVIRUS AGENT; EFAVIRENZ; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION;

CELL LINE; CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV FUSION INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; REPLICATION COMPETENT VIRUSES;

EID: 39149140376     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2007.11.009     Document Type: Article

References (20)

1. Balzarini J., and Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 369 9563 (2007) 787-797
2. Beirnaert E., Willems B., Peeters M., Bouckaert A., Heyndrickx L., Zhong P., Vereecken K., Coppens S., Davis D., Ndumbe P., Janssens W., and van der Groen G. Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay. J. Virol. Methods 73 1 (1998) 65-70
3. Briz V., Poveda E., and Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 57 4 (2006) 619-627
4. Castagna A., and Biswas P. The appealing story of HIV entry inhibitors. From discovery of biological mechanisms to drug development. Drugs 65 7 (2005) 879-904
5. Choudhry V., Zhang M.Y., Harris I., Sidorov I.A., Vu B., Dimitrov A.S., Fouts T., and Dimitrov D.S. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348 3 (2006) 1107-1115
6. Connor R.I., Sheridan K.E., Lai C., Zhang L., and Ho D.D. Characterization of the functional properties of env genes from longterm survivors of human immunodeficiency virus type 1 infection. J. Virol. 70 8 (1996) 5306-5311
7. Hsu M., Buckner C., Harouse J., Gettie A., Blanchard J., Robinson J.E., and Cheng-Mayer C. Antigenic variations in the CD4 induced sites of the CCR5-tropic, pathogenic SHIVSF162P3 gp120 variants. J. Med. Primatol. 32 4-5 (2003) 211-217
8. Ketas T.J., Schader S.M., Zurita J., Teo E., Polonis V., Lu M., Klasse P.J., and Moore J. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 364 2 (2007) 431-440
9. Leonard J.T., and Roy K. The HIV entry inhibitors revisited. Curr. Med. Chem. 13 8 (2006) 911-934
10. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. HIV-1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
11. Lin P.F., Blair W., Wang T., Spicer T., Guo Q., Zhou N., Gong Y., Wang H.G., Rose R., Yamanaka G., Robinson B., Li C.B., Fridell R., Deminie C., Demers G., Yang Z., Zadjura L., Meanwell N., and Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A. 100 19 (2003) 11013-11018
12. Louder M.K., Sambor A., Chertova E., Hunte T., Barrett S., Ojong F., Sanders-Buell E., Zolla-Pazner S., McCutchan F.E., Roser J.D., Gabuzda D., Lifson J.D., and Mascola J.R. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339 2 (2005) 226-238
13. Madani N., Perdigoto A.L., Srinivasan K., Cox J.M., Chruma J.J., LaLonde J., Head M., Smith III A.B., and Sodroski J.G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 78 7 (2004) 3742-2752
14. Markovic I. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curr. Pharm. Des. 12 9 (2006) 1105-1119
15. Schols D. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 71 (2006) 216-226
16. Seibert C., Ying W., Gavrilov S., Tsamis F., Kuhmann S.E., Palani A., Tagat J.R., Clader J.W., McCombie S.W., Baroudy B.M., Smith S.O., Dragic T., Moore J.P., and Sakmar T.P. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349 (2006) 41-54
17. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 6 (2002) 1896-1905
18. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., and Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 78 5 (2007) 2359-2371
19. Zhong P., Peeters M., Janssens W., Fransen K., Heyndrickx L., Vanham G., Willems B., Piot P., and van der Groen G. Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res. Hum. Retroviruses 11 2 (1995) 239-248
20. Xiang S.H., Doka N., Choudhary R.K., Sodroski J., and Robinson J.E. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18 16 (2002) 1207-1217